Analyst Expectations For Myriad Genetics's Future
Analyst Expectations For Myriad Genetics's Future
万基遗传的分析师对未来的预期
The perception of Myriad Genetics by financial experts is analyzed through recent...7 analysts have shared their evaluations of Myriad Genetics (NASDAQ:MYGN) during the recent three months, expressing a mix of bullish and bearish perspectives.
在最近3个月中，有7位分析师对Myriad Genetics(NASDAQ:MYGN)进行了评价，表达了看好和看淡的不同观点。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表总结了他们最近的评级，展示了过去30天内不断变化的情绪，并将其与前几个月进行了比较。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $30.0, a high estimate of $35.00, and a low estimate of $20.00. Observing a 17.65% increase, the current average has risen from the previous average price target of $25.50.
分析师的12个月目标股价揭示了平均目标为$30.0，高估为$35.00，低估为$20.00。观察到17.65%的增长，当前平均价格较之前的平均目标价$25.50有所上升。
Understanding Analyst Ratings: A Comprehensive Breakdown
分析师评级：全面解析
The perception of Myriad Genetics by financial experts is analyzed through recent...
通过最近的分析师行动，分...
登录免费看全文
登录/注册
资讯热榜
更新时间